Clinical Trials Logo
  1. Home
  2. Venous Thrombosis
  3. NCT02892565

Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System) — TACT  

Venous Thrombosis Clinical Trial

Official title:
Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System): Marker of Venous Thrombosis Risk in Systemic Lupus and Antiphospholipid Syndrome? Case-control Study

Clinical Trial Summary

The purpose is to determine the hypercoagulable phenotype by thrombinography associated to an increased risk of symptomatic and objectively confirmed first venous thrombotic event. This is a case-control study in a population with patients having systemic lupus erythematosus (SLE) and/or antiphospholipid antibodies (APL).

Secondary purposes are:

1. To determine the frequency of hypercoagulable phenotype in study population;

2. To analyze the sensibility: consequences of variation of hypercoagulable phenotype threshold on the importance of risk;

3. To identify (genetic and not) factors for hypercoagulable phenotype and their frequency in different groups.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02892565
Study type Interventional
Source Central Hospital, Nancy, France
Contact
Status Completed
Phase N/A
Start date September 2005
Completion date December 2009
View Details
See also
  Status Clinical Trial Phase
Completed NCT02567903 - Tourniquet Study: A Clinical Trial Into the Effect of Tourniquet Use on the Coagulation System N/A
Completed NCT02247414 - Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Phase 4
Recruiting NCT02650453 - Ongoing Registry of Deep Venous Reconstructions N/A
Completed NCT00839657 - Clarification of Optimal Anticoagulation Through Genetics Phase 3
Completed NCT02065388 - Pharmacogenetic Dosing of Warfarin Phase 3
Terminated NCT00872079 - Personalized Warfarin Dosing by Genomics and Computational Intelligence N/A
Terminated NCT00521885 - Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients N/A
Completed NCT00346424 - Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters Phase 3
Active, not recruiting NCT04349189 - Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
Recruiting NCT02238444 - Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Phase 4
Recruiting NCT02597218 - Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.
Completed NCT00986154 - Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Phase 3
Completed NCT00246025 - A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery. Phase 2
Completed NCT00097357 - BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery Phase 2/Phase 3
Completed NCT04645550 - Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT） Phase 4
Recruiting NCT02264743 - Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy Phase 4
Completed NCT01482273 - Ultrasound-enhanced Thrombolysis Versus Standard Catheter Directed Thrombolysis for Ilio-femoral Deep Vein Thrombosis N/A
Recruiting NCT01252420 - Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis Phase 4
Completed NCT01145859 - Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects Phase 1
Completed NCT00790335 - Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Phase 3